103 related articles for article (PubMed ID: 11399867)
1. Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene.
Funato T; Kozawa K; Fujimaki S; Miura T; Kaku M
Chemotherapy; 2001; 47(4):297-303. PubMed ID: 11399867
[TBL] [Abstract][Full Text] [Related]
2. Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells.
Kondo S; Shinomura Y; Kanayama S; Higashimoto Y; Kiyohara T; Zushi S; Kitamura S; Ueyama H; Matsuzawa Y
Oncogene; 1998 Nov; 17(20):2585-91. PubMed ID: 9840921
[TBL] [Abstract][Full Text] [Related]
3. Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells.
Wacheck V; Cejka D; Sieghart W; Losert D; Strommer S; Crevenna R; Monia BP; Selzer E
Cancer Biol Ther; 2006 Oct; 5(10):1348-54. PubMed ID: 16969094
[TBL] [Abstract][Full Text] [Related]
4. Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells.
Boudny V; Murakami Y; Nakano S; Niho Y
Anticancer Res; 1999; 19(6B):5203-6. PubMed ID: 10697535
[TBL] [Abstract][Full Text] [Related]
5. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
Colomer R; Lupu R; Bacus SS; Gelmann EP
Br J Cancer; 1994 Nov; 70(5):819-25. PubMed ID: 7947086
[TBL] [Abstract][Full Text] [Related]
6. Changes in levels of expression of p53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis.
Ikeguchi M; Tatebe S; Kaibara N; Ito H
Eur Surg Res; 1997; 29(5):396-402. PubMed ID: 9323493
[TBL] [Abstract][Full Text] [Related]
7. Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells.
Kaji M; Yonemura Y; Harada S; Liu X; Terada I; Yamamoto H
Cancer Gene Ther; 1996; 3(6):393-404. PubMed ID: 8988842
[TBL] [Abstract][Full Text] [Related]
8. Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines.
Yoo BC; Ku JL; Hong SH; Shin YK; Park SY; Kim HK; Park JG
Int J Cancer; 2004 Feb; 108(4):532-9. PubMed ID: 14696117
[TBL] [Abstract][Full Text] [Related]
9. Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin.
Funato T; Satou J; Kozawa K; Fujimaki S; Miura T; Kaku M
Oncol Rep; 2001; 8(4):807-10. PubMed ID: 11410788
[TBL] [Abstract][Full Text] [Related]
10. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Ciardiello F; Caputo R; Pomatico G; De Laurentiis M; De Placido S; Bianco AR; Tortora G
Int J Cancer; 2000 Mar; 85(5):710-5. PubMed ID: 10699953
[TBL] [Abstract][Full Text] [Related]
11. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.
Ciardiello F; Caputo R; Troiani T; Borriello G; Kandimalla ER; Agrawal S; Mendelsohn J; Bianco AR; Tortora G
Int J Cancer; 2001 Jul; 93(2):172-8. PubMed ID: 11410862
[TBL] [Abstract][Full Text] [Related]
13. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
Gong SJ; Jin CJ; Rha SY; Chung HC
Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides.
Liu X; Pogo BG
Antisense Nucleic Acid Drug Dev; 1996; 6(1):9-16. PubMed ID: 8783791
[TBL] [Abstract][Full Text] [Related]
16. Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells.
Funato T; Kozawa K; Kaku M; Sasaki T
Anticancer Drugs; 2001 Nov; 12(10):829-34. PubMed ID: 11707650
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.
Kim SY; Kim HP; Kim YJ; Oh DY; Im SA; Lee D; Jong HS; Kim TY; Bang YJ
Int J Oncol; 2008 Jan; 32(1):89-95. PubMed ID: 18097546
[TBL] [Abstract][Full Text] [Related]
18. [Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells].
Wu L; Wu A; Jiang K
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):169-72. PubMed ID: 8758793
[TBL] [Abstract][Full Text] [Related]
19. Advancements of antisense oligonucleotides in treatment of breast cancer.
Yang SP; Song ST; Song HF
Acta Pharmacol Sin; 2003 Apr; 24(4):289-95. PubMed ID: 12676065
[TBL] [Abstract][Full Text] [Related]
20. Influence of the proto-oncogene c-fos on cisplatin sensitivity.
Moorehead RA; Singh G
Biochem Pharmacol; 2000 Feb; 59(4):337-45. PubMed ID: 10644041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
